Page last updated: 2024-11-07

mmv665852

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

MMV665852: an antischistosomal agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID95783
CHEMBL ID10835
SCHEMBL ID2683478
MeSH IDM000612679

Synonyms (44)

Synonym
UPCMLD0ENAT5267060:001
MS-8792
n,n'-(di-3,4-dichlorophenyl)urea
4300-43-0
nsc35217
nsc-35217
nsc-70259
nsc70259
1,3-bis(3,4-dichlorophenyl)urea
bdbm25729
us8815951, 299
chembl10835 ,
urea-based compound, 10
nsc 70259
mmv665852
gnf-pf-2903 ,
AKOS001041856
3,3',4,4'-tetrachlorocarbanilide
unii-w5a83c0l6p
urea, n,n'-bis(3,4-dichlorophenyl)-
nsc 35217
w5a83c0l6p ,
3,4,3',4'-tetrachlorodiphenylurea
3'-chloro triclocarban
n,n'-bis(3,4-dichlorophenyl)urea
ZDPIZPXVHVYTOK-UHFFFAOYSA-N
n,n'-bis-(3,4-dichlorophenyl)-urea
SCHEMBL2683478
mfcd00171464
DTXSID20195624
n,n'-bis-(3,4-dichlorophenyl)urea
1,3-bis-(3,4-dichloro-phenyl)-urea
1,3-bis-(3,4-dichlorophenyl)urea
Z44589806
CCG-274085
Q27292329
D83131
mmv-665852
mmv 665852
nsc766782
nsc-766782
CS-0083888
EN300-7390015
SY063491

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
" However, active compounds to date have high cLogP's and are poorly soluble, leading to low bioavailability and thus limiting any therapeutic application."( Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.
Grzegorzewicz, AE; Hess, TN; Jackson, M; Jones, V; Kasagami, T; Kim, IH; Lee, RE; Lenaerts, AJ; McNeil, MR; Merzlikin, O; Morisseau, C; North, EJ; Scherman, MS, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (12)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glucose transporterLeishmania mexicanaIC50 (µMol)12.00000.08102.30676.7450AID1207598
Hexose transporter 1 Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)12.00000.09002.22205.8850AID1207597
Solute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)IC50 (µMol)12.00000.00492.99549.9920AID1207599
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)0.02810.00000.54509.1000AID661405
Calcium-dependent protein kinase 1Plasmodium falciparum 3D7IC50 (µMol)1.00000.00210.00760.0130AID1159502
Epoxide hydrolase BMycobacterium tuberculosis CDC1551IC50 (µMol)0.48000.01900.66403.4000AID1798579
Lysine--tRNA ligase Plasmodium falciparum 3D7IC50 (µMol)2.50000.12000.12000.1200AID1159505
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
central nervous system developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pregnancySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
long-chain fatty acid import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
L-ascorbic acid metabolic processSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cerebral cortex developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to glucose starvationSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor cell maintenanceSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein-containing complex assemblySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to mechanical stimulusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular hyperosmotic responseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to Thyroglobulin triiodothyronineSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to insulinSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
long-chain fatty acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
kinase bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
identical protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Golgi membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female germ cell nucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor inner segmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pronucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
caveolaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
intercalated discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Z discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
midbodySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cortical actin cytoskeletonSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
melanosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
blood microparticleSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transporter complexSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID1370958Half-life in mouse at 46.3 mg/kg, po2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Progress in antischistosomal N,N'-diaryl urea SAR.
AID580920Cytotoxicity against human Raji cells after 72 hrs by Cell titer-glo assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Evaluation of Diarylureas for Activity Against Plasmodium falciparum.
AID1370959Cmax in mouse at 46.3 mg/kg, po2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Progress in antischistosomal N,N'-diaryl urea SAR.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1752698Antischistosomal activity against Schistosoma mansoni Puerto-Rican incubated for 72 hrs by inverted microscopic method2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID639893Aqueous solubility of compound2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents.
AID639897Antiproliferative activity against human CRL2813 cells after 5 days by SRB assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents.
AID1281537Antischistosomal activity against adult stage of Schistosoma japonicum after 72 hrs by microscopy2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Antischistosomal activity of N,N'-arylurea analogs against Schistosoma japonicum.
AID580919Cytotoxicity against human HepG2 cells after 72 hrs by Cell titer-glo assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Evaluation of Diarylureas for Activity Against Plasmodium falciparum.
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID1370956Antischistosomal activity against Schistosoma mansoni Liberian cercariae measured after 72 hrs by microscopic analysis2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Progress in antischistosomal N,N'-diaryl urea SAR.
AID1281535Antischistosomal activity against juvenile stage of Schistosoma japonicum infected in ICR mouse assessed as reduction of parasite burden at 400 mg/kg, po administered as single dose measured after 14 days2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Antischistosomal activity of N,N'-arylurea analogs against Schistosoma japonicum.
AID1281541Antischistosomal activity against Schistosoma mansoni infected in mouse assessed as reduction of parasite burden at 400 mg/kg, po administered as single dose2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Antischistosomal activity of N,N'-arylurea analogs against Schistosoma japonicum.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1752699Antischistosomal activity against Schistosoma mansoni infected in NMRI mouse assessed as worm burden reduction at 400 mg/kg, po administered as single dose for 4 consecutive days and measured after 14 days relative to control2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID1370957Antischistosomal activity against Schistosoma mansoni infected in NMRI mouse assessed as reduction in worm burden at 400 mg/kg, po administered as single dose measured after 14 days relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Progress in antischistosomal N,N'-diaryl urea SAR.
AID205472Inhibitory activity against human soluble epoxide hydrolase2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds.
AID639896Antiproliferative activity against mouse KLN205 cells after 5 days by SRB assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents.
AID205474Inhibitory activity against murine soluble epoxide hydrolase2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds.
AID580918Cytotoxicity against human HEK293 cells after 72 hrs by Cell titer-glo assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Evaluation of Diarylureas for Activity Against Plasmodium falciparum.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID639895Activation of EIF2alpha kinase in human CRL2351 cells assessed as reduction in eIF2-GTP-initiator methionine tRNA ternary complex measuring increase in firefly/renilla luciferase ratio at 5 uM after 16 hrs by dual luciferase reporter gene assay relative t2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents.
AID1752676Antischistosomal activity against Schistosoma mansoni Liberian NTS incubated for 72 hrs by microscopic method2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID1281536Antischistosomal activity against juvenile stage of Schistosoma japonicum after 72 hrs by microscopy2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Antischistosomal activity of N,N'-arylurea analogs against Schistosoma japonicum.
AID1370954Antischistosomal activity against Schistosoma mansoni cercariae infected in NMRI mouse assessed as reduction in worm burden at 100 mg/kg, po administered as single dose via gavage measured after 21 days relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Progress in antischistosomal N,N'-diaryl urea SAR.
AID661405Inhibition of human recombinant soluble epoxide hydrolase using CMNPC as substrate assessed as appearance of 6-methoxy-2-naphthaldehyde after 10 mins by fluorescence analysis2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.
AID580917Cytotoxicity against human BJ cells after 72 hrs by Cell titer-glo assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Evaluation of Diarylureas for Activity Against Plasmodium falciparum.
AID1752703Antischistosomal activity against juvenile Schistosoma japonicum2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1752704Antischistosomal activity against adult Schistosoma japonicum2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID661399Antimycobacterial activity against Mycobacterium tuberculosis H37Ra2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.
AID639898Antiproliferative activity against human CRL2351 cells after 5 days by SRB assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents.
AID1281539Antischistosomal activity against adult stage of Schistosoma japonicum infected in ICR mouse assessed as reduction of parasite burden at 400 mg/kg, po administered as single dose measured after 14 days2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Antischistosomal activity of N,N'-arylurea analogs against Schistosoma japonicum.
AID1798579Mtb EHB Inhibition Assay from Article 10.1016/j.jmb.2008.06.030: \\The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.\\2008Journal of molecular biology, Sep-12, Volume: 381, Issue:4
The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (25.00)29.6817
2010's8 (66.67)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]